首页> 外文期刊>中华医学杂志(英文版) >Comparison of four prognostic models and a new Logistic regression model to predict short-term prognosis of acute-on-chronic hepatitis B liver failure
【24h】

Comparison of four prognostic models and a new Logistic regression model to predict short-term prognosis of acute-on-chronic hepatitis B liver failure

机译:比较四种预后模型和新的Logistic回归模型以预测急性慢性乙型肝炎肝衰竭的短期预后

获取原文
获取原文并翻译 | 示例
           

摘要

Background Acute-on-chronic hepatitis B liver failure (ACLF-HBV) is a clinically severe disease associated with major life-threatening complications including hepatic encephalopathy and hepatorenal syndrome.The aim of this study was to evaluate the short-term prognostic predictability of the model for end-stage liver disease (MELD),MELD-based indices,and their dynamic changes in patients with ACLF-HBV,and to establish a new model for predicting the prognosis of ACLF-HBV.Methods A total of 172 patients with ACLF-HBV who stayed in the hospital for more than 2 weeks were retrospectively recruited.The predictive accuracy of MELD,MELD-based indices,and their dynamic change (△) were compared using the area under the receiver operating characteristic curve method.The associations between mortality and patient characteristics were studied by univariate and multivariate analyses.Results The 3-month mortality was 43.6%.The largest concordance (c) statistic predicting 3-month mortality was the MELD score at the end of 2 weeks of admission (0.8),followed by the MELD:sodium ratio (MESO) (0.796) and integrated MELD (iMELD) (0.758) scores,△MELD (0.752),△MESO (0.729),and MELD plus sodium (MELD-Na) (0.728) scores.In multivariate Logistic regression analysis,the independent factors predicting prognosis were hepatic encephalopathy (OR=-3.466),serum creatinine,international normalized ratio (INR),and total bilirubin at the end of 2 weeks of admission (OR=10.302,6.063,5.208,respectively),and cholinesterase on admission (OR=0.255).This regression model had a greater prognostic value (c=0.85,95% Cl 0.791-0.909) compared to the MELD score at the end of 2 weeks of admission (Z=4.9851,P=-0.0256).Conclusions MELD score at the end of 2 weeks of admission is a useful predictor for 3-month mortality in ACLF-HBV patients.Hepatic encephalopathy,serum creatinine,international normalized ratio,and total bilirubin at the end of 2 weeks of admission and cholinesterase on admission are independent predictors of 3-month mortality.
机译:背景慢性乙型肝炎急性肝衰竭(ACLF-HBV)是一种临床严重疾病,伴有严重的危及生命的并发症,包括肝性脑病和肝肾综合征。本研究的目的是评估肝癌的短期预后可预测性。终末期肝病(MELD)模型,基于MELD的指标及其在ACLF-HBV患者中的动态变化,并建立新的预测ACLF-HBV患者预后的模型。方法共有172例ACLF患者回顾性研究入院2周以上的-HBV。使用受试者工作特征曲线法下的面积比较MELD,MELD指标的预测准确性及其动态变化(△)。结果:3个月死亡率为43.6%。最大预测3个月死亡率的一致性(c)为ME,3个月死亡率为43.6%。入院2周结束时的LD分数(0.8),其次是MELD:钠比(MESO)(0.796)和综合MELD(iMELD)(0.758)分数,△MELD(0.752),△MESO(0.729),在多元Logistic回归分析中,预测预后的独立因素是肝性脑病(OR = -3.466),血清肌酐,国际标准化比值(INR)和总胆红素。入院2周后(分别为OR = 10.302、6.063、5.208)和入院时胆碱酯酶(OR = 0.255)。该回归模型的预后价值较高(c = 0.85,95%Cl 0.791-0.909)入院2周末的MELD评分(Z = 4.9851,P = -0.0256)。结论入院2周末的MELD评分是ACLF-HBV患者3个月死亡率的有用预测指标。入院2周时的血清肌酐,国际标准化比率和总胆红素与入院时胆碱酯酶是独立的3个月死亡率的冰霜。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2012年第13期|2272-2278|共7页
  • 作者单位

    Liver Failure Therapy and Research Centre, 302 Hospital of People's Liberation Army, Beijing 100039, China;

    Liver Failure Therapy and Research Centre, 302 Hospital of People's Liberation Army, Beijing 100039, China;

    Liver Failure Therapy and Research Centre, 302 Hospital of People's Liberation Army, Beijing 100039, China;

    Liver Failure Therapy and Research Centre, 302 Hospital of People's Liberation Army, Beijing 100039, China;

    Liver Failure Therapy and Research Centre, 302 Hospital of People's Liberation Army, Beijing 100039, China;

    Liver Failure Therapy and Research Centre, 302 Hospital of People's Liberation Army, Beijing 100039, China;

    Liver Failure Therapy and Research Centre, 302 Hospital of People's Liberation Army, Beijing 100039, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号